Clinical Trial Update: Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 study of CD19-directed allogeneic memory T-cell therapy for relapsed or refractory acute lymphoblastic leukemia in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19-directed allogeneic memory T-cell therapy

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory | Phase 1 | Status: RECRUITING